United States valuation of EQ-5D-5L health states using an international protocol AS Pickard, EH Law, R Jiang, E Pullenayegum, JW Shaw, F Xie, M Oppe, ... Value in Health 22 (8), 931-941, 2019 | 196 | 2019 |
Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research EH Law, M Leung Annals of Pharmacotherapy 49 (3), 335-342, 2015 | 77 | 2015 |
Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 60 | 2020 |
Association between proton pump inhibitors and microscopic colitis: implications for practice and future research EH Law, M Badowski, YT Hung, K Weems, A Sanchez, TA Lee Annals of Pharmacotherapy 51 (3), 253-263, 2017 | 46 | 2017 |
Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study Z Zhou, P Chaudhari, H Yang, AP Fang, J Zhao, EH Law, EQ Wu, R Jiang, ... Diabetes Therapy 8, 555-571, 2017 | 38 | 2017 |
Parallel valuation: a direct comparison of EQ-5D-3L and EQ-5D-5L societal value sets EH Law, AS Pickard, F Xie, SM Walton, TA Lee, A Schwartz Medical Decision Making 38 (8), 968-982, 2018 | 28 | 2018 |
Racial and ethnic differences in risk of second primary cancers among breast cancer survivors GS Calip, EH Law, NY Ko Breast cancer research and treatment 151, 687-696, 2015 | 24 | 2015 |
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis EM Salvo, AO Ramirez, J Cueto, EH Law, A Situ, C Cameron, IA Samjoo The Breast 57, 5-17, 2021 | 23 | 2021 |
A comparison of self-rated health using EQ-5D VAS in the United States in 2002 and 2017 AS Cha, EH Law, JW Shaw, AS Pickard Quality of Life Research 28, 3065-3069, 2019 | 15 | 2019 |
Target-specific oral anticoagulants in patients undergoing cardioversion EH Law, W Gordon American journal of health-system pharmacy 71 (14), 1171-1176, 2014 | 13 | 2014 |
Clinical trajectories, healthcare resource use, and costs of diabetic nephropathy among patients with type 2 diabetes: a latent class analysis R Jiang, E Law, Z Zhou, H Yang, EQ Wu, R Seifeldin Diabetes therapy 9, 1021-1036, 2018 | 9 | 2018 |
Increasing uptake of comparative effectiveness and patient-centered outcomes research among stakeholders: insights from conference discussion E Law, R Harrington, GC Alexander, S Saha, E Oehrlein, EM Perfetto Journal of comparative effectiveness research 7 (2), 181-191, 2018 | 9 | 2018 |
Health-related quality of life among patients with HR+/HER2–early breast cancer C Criscitiello, D Spurden, J Piercy, A Rider, R Williams, D Mitra, R Wild, ... Clinical Therapeutics 43 (7), 1228-1244. e4, 2021 | 7 | 2021 |
Choice blindness and health-state choices among adolescents and adults EH Law, AL Pickard, A Kaczynski, AS Pickard Medical Decision Making 37 (6), 680-687, 2017 | 7 | 2017 |
Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: Is early treatment associated with improved outcomes? P Chaudhari, C Vallarino, EH Law, R Seifeldin Diabetes Research and Clinical Practice 122, 162-169, 2016 | 7 | 2016 |
A primer on latent class analysis EH Law, R Harrington Value & Outcomes Spotlight 2 (6), 18-19, 2016 | 7 | 2016 |
Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points E Law, R Gavanji, S Walsh, A Haltner, R McTavish, C Cameron Journal of Comparative Effectiveness Research 11 (2), 109-120, 2021 | 6 | 2021 |
The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students EH Law, R Jiang, A Kaczynski, A Mühlbacher, AS Pickard American Journal of Pharmaceutical Education 83 (7), 2019 | 6 | 2019 |
United States valuation of EQ-5D-5L health States: An initial model using a standardized protocol AS Pickard, EH Law, R Jiang, M Oppe, JW Shaw, F Xie, KS Boye, ... Value in Health 21, S4-S5, 2018 | 6 | 2018 |
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran TS Leung, EH Law Drug Design, Development and Therapy, 3557-3569, 2015 | 6 | 2015 |